Parvovirus B19 is a common virus that infects humans and is best known for causing “fifth disease,” a childhood illness marked by a bright red rash on the cheeks. It spreads through respiratory droplets and specifically targets the cells in your bone marrow that produce red blood cells. Most healthy people recover without any treatment, but the virus can cause serious complications during pregnancy, in people with blood disorders like sickle cell disease, and in those with weakened immune systems.
How the Virus Works in Your Body
Parvovirus B19 is unusually picky about which cells it infects. It latches onto a specific molecule called globoside (also known as P antigen) found on the surface of red blood cell precursors in bone marrow. These are the young cells your body is actively growing into mature red blood cells. The virus can’t infect stem cells or white blood cell lines, only this narrow population of red blood cell “factories.” People who genetically lack this surface molecule are naturally resistant to infection.
Once inside a cell, the virus hijacks the cell’s own DNA-copying machinery to reproduce. It forces the cell into a state of arrested development, stuck mid-division, while it churns out copies of itself. This kills the host cell in the process. Because the virus wipes out the cells responsible for making new red blood cells, your body temporarily stops producing them. In a healthy person with normal red blood cell lifespan, this brief pause goes unnoticed. But in someone whose red blood cells already break down faster than usual, the gap in production can trigger a dangerous drop in blood counts.
How It Spreads
The virus travels primarily through respiratory secretions: coughing, sneezing, and close person-to-person contact. You can also contract it through contaminated blood products or, if you’re pregnant, pass it to your fetus. The incubation period runs about 1 to 1.5 weeks, with the characteristic rash typically appearing around 16 to 17 days after exposure. Importantly, the most contagious window is before the rash shows up, which makes it difficult to prevent spread in schools and households.
Symptoms in Children
In children, parvovirus B19 often begins with mild cold-like symptoms: low fever, headache, and a runny nose. About a week later, the hallmark “slapped cheek” rash appears, giving both cheeks an intensely red, flushed look. A lacy, net-like rash may then spread to the arms, legs, and trunk. By the time the rash is visible, the child is typically no longer contagious and feels mostly fine. The rash can fade and reappear over several weeks, sometimes triggered by sunlight, warm baths, or exercise, but it doesn’t indicate worsening illness.
Some children have such mild symptoms that the infection passes without anyone noticing. Others never develop the rash at all. Fifth disease got its name because it was historically the fifth in a list of common childhood rash illnesses, alongside measles, scarlet fever, rubella, and a condition now rarely discussed.
Symptoms in Adults
Adults with parvovirus B19 have a noticeably different experience. The classic facial rash is uncommon. Instead, about 60% of adolescents and adults develop joint pain and swelling, often in the hands, wrists, and knees. The pattern can mimic rheumatoid arthritis closely enough to cause diagnostic confusion.
Symptoms typically resolve within three weeks, but roughly 20% of adults have joint problems that linger for months or even years. Adults may also experience fatigue, general achiness, and a more subtle rash on the body. Because the presentation looks so different from the childhood version, many adults don’t realize they’ve had parvovirus B19 at all.
Serious Complications
Transient Aplastic Crisis
For people with sickle cell disease, hereditary spherocytosis, or other conditions where red blood cells break down faster than normal, parvovirus B19 can trigger a transient aplastic crisis. The virus shuts down red blood cell production in bone marrow at a time when the body is already struggling to keep up. The result is a rapid, sometimes life-threatening drop in red blood cell counts that often requires hospitalization and blood transfusions. This complication is especially common in young children with sickle cell disease.
Chronic Infection in Immunocompromised People
If your immune system is suppressed (from chemotherapy, organ transplant medications, or HIV, for example), your body may fail to clear the virus. Instead of the short-lived infection healthy people experience, the virus persists and continually destroys red blood cell precursors, causing severe, ongoing anemia called pure red cell aplasia. This can require treatment with concentrated antibodies to help the immune system finally eliminate the virus.
Risks During Pregnancy
Parvovirus B19 infection during pregnancy can cross the placenta. Vertical transmission occurs in about 39% of pregnancies where the mother is infected. The virus targets fetal red blood cell precursors and fetal tissues. The risk is highest between weeks 17 and 24 of pregnancy, when the placenta expresses elevated levels of the receptor the virus needs and the fetal liver is intensely producing blood cells.
In severe cases, the fetus develops hydrops fetalis, a condition where severe anemia leads to fluid buildup in fetal tissues and body cavities. This can result in the need for fetal blood transfusions or, in some cases, pregnancy loss. Many maternal infections cause no fetal harm, but the potential severity makes it a concern worth monitoring.
How It’s Diagnosed
Doctors diagnose parvovirus B19 through blood tests that look for two types of antibodies. IgM antibodies appear first, about 10 to 12 days after infection, and indicate a recent or current infection. IgG antibodies develop around two weeks after infection and remain detectable for life, serving as a marker of past immunity.
The interpretation depends on which antibodies are present. If both IgM and IgG are positive, you likely have a recent or acute infection. If only IgG is positive, you’ve been infected at some point in the past and are now immune. If both are negative, you’ve never been exposed. Ninety percent of people who show up with the classic facial rash already have detectable IgM antibodies at that first visit. In cases involving serious anemia or joint symptoms, IgM is usually present by the third day of illness.
IgM antibodies remain detectable for two to four months after infection, so a positive IgM result doesn’t always mean the infection is happening right now.
Treatment
For the vast majority of people, parvovirus B19 requires no treatment. The infection runs its course, and the body clears the virus on its own. Over-the-counter pain relievers can help with joint pain and fever. The rash doesn’t need treatment.
People who develop transient aplastic crisis typically need blood transfusions to bridge the gap until their bone marrow recovers. For immunocompromised patients with chronic infection and pure red cell aplasia, intravenous immunoglobulin therapy is considered first-line treatment. This delivers concentrated antibodies that help the body fight the virus it can’t clear on its own. Reducing immunosuppressive medications, when possible, can also help the immune system regain control.
Pregnant women who are infected are monitored with ultrasound to watch for signs of fetal anemia or hydrops. If the fetus develops severe anemia, intrauterine blood transfusions can be performed.
Recent Surge in Cases
In August 2024, the CDC issued a health advisory about a significant increase in parvovirus B19 activity across the United States. The proportion of people with IgM antibodies (indicating recent infection) jumped from under 3% to 10% in June 2024. Among children aged 5 to 9, the increase was dramatic: from 15% to 40%. Parvovirus B19 DNA detected in plasma donor samples rose from 1.5% in December 2023 to nearly 20% by June 2024.
The CDC also reported more cases than expected among pregnant women, including cases of severe fetal anemia requiring transfusions or resulting in pregnancy loss, along with increased aplastic crisis episodes in people with sickle cell disease. There is no routine national surveillance system for parvovirus B19 in the United States, which means case counts rely on laboratory data and clinician reports rather than a comprehensive tracking system. Periodic surges are expected with this virus, as new cohorts of children are born without immunity, but the 2024 spike was notable for its scale.